PALOMA-3 clinical trial: Is there a significant benefit in overall survival for breast cancer? Is it worth it?

Jacob J. Adashek, Pedro N. Aguiar, Pedro Castelo-Branco, Gilberto L. Lopes, Ramon Andrade De Mello

Research output: Contribution to journalComment/debatepeer-review

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)1407-1410
Number of pages4
JournalFuture Oncology
Volume15
Issue number13
DOIs
StatePublished - May 2019

Keywords

  • CDK inhibitors
  • hormone-positive HER-2-negative advanced breast cancer
  • overall survival
  • Phase III

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this